These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29676351)

  • 1. Evaluation of p53 protein expression in Barrett esophagus.
    Krothapalli M; Kini JR; Kini H; Sahu KK; Shenoy S; Krishna SG; Tantry BV
    Indian J Pathol Microbiol; 2018; 61(2):170-175. PubMed ID: 29676351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of "indefinite for dysplasia" grading in Barrett metaplasia.
    Younes M; Lauwers GY; Ertan A; Ergun G; Verm R; Bridges M; Woods K; Meriano F; Schmulen C; Johnson C; Barroso A; Schwartz J; McKechnie J; Lechago J
    Arch Pathol Lab Med; 2011 Apr; 135(4):430-2. PubMed ID: 21466357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of cyclin A immunohistochemistry for cancer risk stratification in Barrett esophagus surveillance: A multicenter case-control study.
    van Olphen SH; Ten Kate FJC; Doukas M; Kastelein F; Steyerberg EW; Stoop HA; Spaander MC; Looijenga LHJ; Bruno MJ; Biermann K;
    Medicine (Baltimore); 2016 Nov; 95(47):e5402. PubMed ID: 27893678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.
    van Olphen S; Biermann K; Spaander MC; Kastelein F; Steyerberg EW; Stoop HA; Bruno MJ; Looijenga LH
    Am J Gastroenterol; 2015 Oct; 110(10):1420-8. PubMed ID: 26323187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDX-2 Expression in Esophageal Biopsies Without Goblet Cell Intestinal Metaplasia May Be Predictive of Barrett's Esophagus.
    Saller J; Al Diffalha S; Neill K; Bhaskar RA; Oliveri C; Boulware D; Levine H; Kalvaria I; Corbett FS; Khazanchi A; Klapman J; Coppola D
    Dig Dis Sci; 2020 Jul; 65(7):1992-1998. PubMed ID: 31691172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Foveolar type dysplasia in Barrett esophagus.
    Brown IS; Whiteman DC; Lauwers GY
    Mod Pathol; 2010 Jun; 23(6):834-43. PubMed ID: 20228780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
    Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
    Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia.
    Younes M; Lechago J; Chakraborty S; Ostrowski M; Bridges M; Meriano F; Solcher D; Barroso A; Whitman D; Schwartz J; Johnson C; Schmulen AC; Verm R; Balsaver A; Carlson N; Ertant A
    Scand J Gastroenterol; 2000 Feb; 35(2):131-7. PubMed ID: 10720109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Goblet cell mimickers in esophageal biopsies are not associated with an increased risk for dysplasia.
    Younes M; Ertan A; Ergun G; Verm R; Bridges M; Woods K; Meriano F; Schmulen AC; Colman R; Johnson C; Barroso A; Schwartz J; McKechnie J; Lechago J
    Arch Pathol Lab Med; 2007 Apr; 131(4):571-5. PubMed ID: 17425386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
    Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
    Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
    Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
    Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence or absence of intestinal metaplasia but not its burden is associated with prevalent high-grade dysplasia and cancer in Barrett's esophagus.
    Bansal A; McGregor DH; Anand O; Singh M; Rao D; Cherian R; Wani SB; Rastogi A; Singh V; House J; Jones PG; Sharma P
    Dis Esophagus; 2014; 27(8):751-6. PubMed ID: 24165297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic Raman spectroscopy enables objective diagnosis of dysplasia in Barrett's esophagus.
    Almond LM; Hutchings J; Lloyd G; Barr H; Shepherd N; Day J; Stevens O; Sanders S; Wadley M; Stone N; Kendall C
    Gastrointest Endosc; 2014 Jan; 79(1):37-45. PubMed ID: 23886354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
    Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
    Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia.
    Chen X; Liu BL; Harpaz N; Zhu H; Polydorides AD; Liu Q
    Histopathology; 2023 Feb; 82(3):454-465. PubMed ID: 36251540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.
    van Dekken H; Hop WC; Tilanus HW; Haringsma J; van der Valk H; Wink JC; Vissers KJ
    Am J Clin Pathol; 2008 Nov; 130(5):745-53. PubMed ID: 18854267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
    Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
    World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.